Authors
Latest:
20 Years of Trials, Hope and Progress for Patients with Pancreatic AdenocarcinomaIn a comprehensive review of the last 20 years of advancements and challenges in the pancreatic adenocarcinoma landscape, Dr. Tomsilav Dragovich highlights how treatment has evolved for this patient population.
Latest:
Future Treatment Landscape for RRMMMultiple myeloma expert, Dr Clifton Mo, shares his insights on future directions for the treatment of multiple myeloma.
Latest:
Tackling Cancer Care in the Face of Climate ChangeLeticia Nogueira, PhD, MPH, discusses how healthcare professionals and patients can come together facing the threats of climate change on cancer care.
Latest:
Behind the FDA Approval of Fruquintinib for Previously Treated mCRCIn season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer.
Latest:
Integrating Personalized Medicine: Advice for Medical OncologistsTracy Proverbs-Singh, MD, and Steven Lee-Kong, MD, reflect on how to incorporate sequencing and personalized treatments effectively in oncology practice.
Latest:
TIL Quantity Greatly Impacts Survival in Metastatic Breast CancerIn an interview with Targeted Oncology, Daniel G. Stover, MD, highlighted the objective to enhance delivery of endocrine therapy plus CDK4/6 inhibitors to patients with hormone receptor-positive, HER2-negative breast cancer by utilizing biomarker assessments as a guide to interchange or cease treatment at the most favorable time.
Latest:
Concluding Remarks for the Current Use of ctDNA Testing for Treatment Decisions in stage II-III CRCYoshiaki Nakamura, MD, PhD, discusses the quantification threshold for tissue-free ctDNA in detecting residual tumor fractions, highlights additional mutations and hypermethylated loci identified by epigenomic assays, and examines how these assays complement current radiographic monitoring in stage II to III CRC while also considering their evolving role in identifying MRD to enhance recurrence-free survival.
Latest:
Exploring the Updated Efficacy of the CheckMate 214 Trial in RCCUlka N. Vaishampayan, MBBS, FAB, discusses the updated data from CheckMate 214 of nivolumab and ipilimumab versus sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma.
Latest:
Pano/GemBuMel is Safe and Effective in High-Risk or Relapsed/Refractory MyelomaYago Nieto, MD, PhD, discusses the findings from a phase 2 trial evaluating treatment with panobinostat, gemcitabine, busulfan, and melphalan for high-risk or relapsed/refractory myeloma.
Latest:
Administering CAR T-Cell Therapy in the Community SettingPeter A. McSweeney, MD, discusses the challenges that come with administering chimeric antigen receptor T-cell therapy. He also explains how CAR T cells entering the second-line may change the ways community practices choose treatments for their patients.
Latest:
PFS Provides Rationale for Dato-DXd vs Chemo in HR+, HER2– Breast CancerChristos Vaklavas, MD, discusses the results of the TROPION-Breast01 trial of datopotamab deruxtecan in patients with metastatic breast cancer.
Latest:
Andorsky on the Shifting Treatment Landscape of BTKi Use in CLL/SLLDavid J. Andorsky, MD, discusses findings from a retrospective study of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma from ASH 2023.
Latest:
Considering the Changing Treatment Landscape for Patients With MelanomaEvan Lipson, MD, discusses the evolving treatment landscape for advanced melanoma.
Latest:
Mechanism and Benefits of Rusfertide in Polycythemia VeraAniket Bankar, MD, discusses why rusfertide is considered a promising therapeutic approach for patients with polycythemia vera.
Latest:
Matasar Discusses Odronextamab and the ELM-1 TrialMatthew Matasar, MD, discusses odronextamab and the ongoing phase 1 ELM-1 trial in patients with CD20-positive B-cell malignancies.
Latest:
World Neuroendocrine Cancer Awareness Day: Therapeutic Options for Well-differentiated NETsAjaz M. Khan, MD, MBA, CPE, a medical oncologist and chair of the CTCA Department of Medical Oncology, explores available treatments for patients with well-differentiated neuroendocrine tumors.
Latest:
Exploring the Role of Gut Microbiome in Cancer TherapyThe normal gut microbiota metabolizes nutrients and drugs, maintains the gut mucosal barrier integrity, protects against pathogens, and trains and develops the immune system. The gut microbiome has been implicated in many human pathologies.
Latest:
Navigating Treatment Choices in Urothelial CancerGuru P. Sonpavde, MD, provides insights on the phase 3 CheckMate 901 trial and explains what a community oncologist should know about the use of concurrent frontline nivolumab plus chemotherapy in metastatic or unresectable urothelial carcinoma based on this study.
Latest:
Sequencing Osimertinib in Patients With EGFR-Mutated NSCLCAparna Hegde, MD, discusses the decision to use osimertinib as soon as possible in patients with EGFR-positive non–small cell lung cancer.
Latest:
Liver Cancer Awareness Month: A Decade of Progress and Hope in Hepatocellular CarcinomaMahvish Muzaffar, MD, and Nasreen Vohra, MD, from the Brody School of Medicine/East Carolina University, discuss the past decade of progress in treatment for patients with hepatocellular carcinoma.
Latest:
CLL Treatment Advances and Frontline Therapy Insights With Dr. KhanCyrus M. Khan, MD, discusses how treatment paradigms for chronic lymphocytic leukemia have changed in recent years, particularly regarding frontline therapy options.
Latest:
Early Trial Targeting CLL1-Positive Cells Demonstrates Efficacy in Pediatric AMLA small clinical trial of pediatric patients with relapsed/refractory acute myeloid leukemia showed efficacy and safety with anti-C-type lectin-like molecule-based chimeric antigen receptor T cells.
Latest:
Post–COVID-19 Infection Remains a Concern in Patients With CancerMany questions remain unanswered about COVID-19, and we are now experiencing another problem—postacute sequelae of SARS-CoV-2 infection, also referred to as post–COVID-19 condition or post-COVID syndrome.
Latest:
ESMO 2024: Key Updates From NICHE-2Panelists discuss how NICHE-2 trial updates offer valuable insights into the role of minimal residual disease assessment in guiding neoadjuvant immunotherapy for colorectal cancer patients.
Latest:
Key Conferences Shape the Future of Cell and Gene TherapyJoe DePinto, MBA, discusses the complexity of the cell and gene therapy ecosystem and the need for collaboration with partners to support it effectively.
Latest:
Community Oncologist Perspective: Future of Bispecific Therapies for NHLDr Graff discusses perceptions of the future for patients treated with bispecific antibodies for non-Hodgkin lymphoma, highlighting key unmet needs and sharing clinical pearls for community oncologists.
Latest:
Advancing Cancer Care: NYU Langone’s Molecular Oncology ProgramAlec Kimmelman, MD, PhD, and Shridar Ganesan, MD, PhD, discuss the institution's new molecular oncology program.
Latest:
Treating Patients With Prostate Cancer During COVID-19 Era Poses New ChallengesMonica L. Baskin, PhD, addresses the biggest challenges in treating patients with prostate cancer during the COVID-19 era.
Latest:
Emerging Treatments in Ovarian Cancer and Advice for Community OncologistsDr Chirag A. Shah highlights novel emerging treatments in ovarian cancer and provides advice for community oncologists.
